(NASDAQ: AVDL) Avadel Pharmaceuticals's forecast annual revenue growth rate of 45.23% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.84%.
Avadel Pharmaceuticals's revenue in 2025 is $138,160,000.On average, 5 Wall Street analysts forecast AVDL's revenue for 2025 to be $24,247,836,737, with the lowest AVDL revenue forecast at $23,787,806,802, and the highest AVDL revenue forecast at $24,544,244,797. On average, 4 Wall Street analysts forecast AVDL's revenue for 2026 to be $33,417,214,295, with the lowest AVDL revenue forecast at $32,165,478,046, and the highest AVDL revenue forecast at $35,505,368,607.
In 2027, AVDL is forecast to generate $40,407,761,344 in revenue, with the lowest revenue forecast at $39,276,958,813 and the highest revenue forecast at $42,518,560,615.